Danaher Co. (NYSE:DHR) Shares Sold by Roffman Miller Associates Inc. PA

Roffman Miller Associates Inc. PA lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,301 shares of the conglomerate’s stock after selling 1,149 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Danaher were worth $10,249,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Nicholas Hoffman & Company LLC. increased its holdings in shares of Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares during the period. Drive Wealth Management LLC increased its holdings in Danaher by 3.1% in the fourth quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock worth $344,000 after buying an additional 44 shares during the last quarter. Trust Investment Advisors increased its holdings in Danaher by 1.8% in the fourth quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock worth $650,000 after buying an additional 49 shares during the last quarter. Connolly Sarah T. increased its holdings in Danaher by 0.5% in the third quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock worth $2,382,000 after buying an additional 50 shares during the last quarter. Finally, Austin Private Wealth LLC increased its holdings in Danaher by 3.4% in the third quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock worth $389,000 after buying an additional 51 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,132 shares of company stock worth $21,022,795. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

Danaher stock traded up $1.73 during mid-day trading on Friday, hitting $247.53. 1,714,820 shares of the company were exchanged, compared to its average volume of 2,773,065. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The business has a fifty day moving average of $248.94 and a 200 day moving average of $230.88. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a market capitalization of $183.34 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 4.19 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the prior year, the company posted $2.36 earnings per share. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Co. will post 7.64 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of recent analyst reports. Royal Bank of Canada upped their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp upped their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Robert W. Baird upped their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their target price for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Raymond James upped their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $270.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.